Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01256372
Other study ID # AP214-CS007
Secondary ID
Status Completed
Phase Phase 2
First received December 5, 2010
Last updated March 14, 2012
Start date October 2010
Est. completion date August 2011

Study information

Verified date March 2012
Source Action Pharma A/S
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationDenmark: Danish Medicines Agency
Study type Interventional

Clinical Trial Summary

This study investigates the effect of two dose-levels of AP214 on the prevention of (acute) kidney injury after cardiac surgery.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date August 2011
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Has signed the trial-specific informed consent form.

2. Patients = 18 years old, male or female, not of childbearing potential (postmenopausal or permanently sterilized, e.g. tubal ligation, hysterectomy, bilateral salpingectomy), regardless of ethnicity.

3. Patients undergoing combined coronary artery bypass grafting (CABG) surgery and surgery of one or more cardiac valve (valve(s) surgery), or

4. Patients undergoing surgery of more than one cardiac valve (valves surgery), or

5. Patients undergoing surgery of the aortic root or ascending part of the aorta, or

6. Patients undergoing surgery of the aortic root or ascending part of the aorta, combined with CABG and/or valve(s) surgery, or

7. Patients with stage III chronic kidney disease (eGFR 30-59 ml/min determined by the Modification of Diet in Renal Disease (MDRD formula)) undergoing CABG or Valve surgery

Exclusion Criteria:

1. Cardiac surgery to be performed "off pump" without cardiopulmonary bypass.

2. Cardiac surgery to be performed with hypothermic circulatory arrest.

3. Confirmed or suspected endocarditis.

4. EF = 20%, evaluated within 2 months prior to screening visit.

5. Requiring a reoperation on one of the valves within 3 months following the original valve surgical procedure.

6. Active peptic ulcer disease and gastritis.

7. Receiving dopamine, adrenalin or noradrenalin at any dose at any time 14 days prior to Day of surgery.

8. Known or suspected hypersensitivity to the investigational medicinal product.

9. Current participation in any other interventional clinical trial.

10. Previously dosed with AP214.

11. Use of investigational medicinal products within the previous 6 months.

12. Body weight above 130 kg.

13. History of any organ transplant.

14. Women who are of childbearing potential, pregnant, or breast-feeding.

15. Current abuse of alcohol or substance, according to the investigator's medical judgment.

16. Has a mental incapacity or language barriers precluding adequate understanding of trial procedures.

17. Any history of cancer within the last 2 years

18. Any history of dialysis.

19. Is considered by the Investigator unsuitable to participate in the trial for any other reason, for instance due to a significant serious underlying condition.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Drug:
AP214
AP214
Placebo
Placebo; intravenous infusion

Locations

Country Name City State
Denmark University Hospital Copenhagen, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Action Pharma A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Tolerability To assess the safety and tolerability of AP214 compared to placebo; by analysis of number and nature of Adverse Events (AEs), Serious Adverse Events (SAEs), changes in laboratory parameters and overall health status 90 days Yes
Primary Efficacy To assess the effect of AP214 versus placebo on the maximal postoperative change in absolute values of Serum Creatinine (SCr) compared to baseline within the first 7 days after surgery or until discharge from hospital, whichever comes first 7 days No
Secondary Efficacy To assess the ability of AP214 compared to placebo to reduce postoperative changes in SCr, and eGFR at day 28, 60 and Day 90 and GFR at Day 90 compared to baseline 90 days No
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2